Why the study?
Does ristocetin differentiate von Willebrand's disease into two groups based on platelet aggregation?
Does ristocetin differentiate von Willebrand's disease into two groups based on platelet aggregation?
Ristocetin can be used to differentiate von Willebrand's disease into two groups based on platelet aggregation response.
Answers are grounded in this paper and cite their sources.
Ristocetin response may distinguish vWD subgroups; leaves open diagnostic utility pending prospective validation.
Earlier studies have shown that patients with von Willebrand’s disease are considered to have normal platelets, but they lack at least one plasma protein. Results are presented indicating that ristocetin, known to aggregate normal platelets, fails to cause platelet aggregation in the group of von Willebrand’s disease patients exhibiting no platelet adhesiveness. It is postulated that there may be two groups of patients within von Willebrand’s disease and, further, that ristocetin will provide a useful approach to study the plasma deficiency or abnormality in von Willebrand’s disease.
No takes yet. Share an insight, caveat, or question.
Howard et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: